CanaQuest Medical Corp Overview

Comprehensive Solution for Epilepsy Drug Commercialization and a Platform for Future Neurological Treatments

Q4 - 2024

CanaQuest provides a complete, end-to-end solution for the commercialization of an epilepsy drug, supported by the following:

- **Regulatory:** We are preparing New Drug Applications (NDAs) for Phase II/III clinical trials with Health Canada and the US FDA, aiming to secure seven years of market exclusivity through the FDA's Orphan Drug Status.
- **Experienced Scientific Team:** Our team played a pivotal role in the successful launch of *Epidiolex* by GW Pharma.
- **Synergistic Effect:** Our drug candidate, *CQ-001*, enhances efficacy through the synergistic action of three molecules that bond with PPAR receptors.
- **CDMO Manufacturer:** Access to ISO 17025-certified, pharmaceutical-quality facilities in Canada, USA, Europe, and India.

This foundation sets the stage for future treatments targeting neurological conditions such as depression, anxiety, and PTSD.

Accumulated Expertise

CanaQuest has assembled a world-class team to advance *CQ-001* through regulatory approval and commercialization:

1. **Dr. Jordyn Stuart, Ph.D., BS, BS – Acting Chief Scientific Officer:** With 12 years of pre-clinical cannabinoid research, including six years at Greenwich Biosciences (GW Pharma), Dr. Stuart contributed to the launch of *Epidiolex*®.
2. **Dr. Hunter Land, Ph.D., MS – Chief Scientific Advisor:** Co-led the clinical development of *Epidiolex*® at GW Pharma and advises on all clinical trials and studies.
3. **Eddie Francis, MS – Interim Chief Operating Officer:** With a background in Molecular Biology and Oncology, Eddie has over 10 years in natural therapeutics and 20 years in private-sector mental health and wellness initiatives.
4. **Dr. Paul Dick, DVM, MSc – Chairman of Advisory Board:** With over 30 years in the pharmaceutical and animal health industries, Dr. Dick has served on numerous boards, including the Animal Health Institute.
5. **Neil Kothari, J.D. LLB, CA, CFA – Fractional Counsel:** An expert in International Finance, Securities Law, and M&A, Neil has deep expertise in IP, product licensing, and online platform development.

Market Potential

Epilepsy affects 1.2% of the global population, with 30% of patients suffering from refractory epilepsy, resistant to current treatments. *Epidiolex* has seen a 25% patient drop-off due to side effects from high CBD dosages. CanaQuest offers a more effective and better-tolerated alternative, with the potential to capture 25% of GW Pharma's $845M market share as of 2023.

- **Drug Candidate:** *CQ-001* has the potential to outperform existing treatments like *Epidiolex*® at lower dosages with fewer side effects. Future versions are planned for neurological conditions such as depression, anxiety, and PTSD.
- **Pre-Clinical Trials:** Rodent trials conducted at Western University and MES mouse models for epilepsy at the Ontario Brain Institute demonstrated that *CQ-001* showed a 35% increase in potency compared to isolated cannabidiol, offering significantly greater seizure protection.

Partnerships

CanaQuest has established strategic partnerships with Neeka Health, the NHL Alumni Association for Clinical Studies, and experts in clinical trials. These collaborations will explore potential applications of CQ-001 for various indications, paving the way for future clinical trials.

Awards and Recognition

CanaQuest has been awarded, *Medical Cannabinoid Development Company of the Year 2024* and *Endocannabinoid Therapeutics Development Company* of the Year 2024 by Global Health & Pharma, UK in its ninth annual Healthcare and Pharmaceutical Awards.

Exit Strategy

Our exit strategy includes an uplisting and a potential acquisition by a large pharmaceutical company. The $7.2 billion acquisition of GW Pharma by Jazz Pharma serves as a notable precedent.

Investment Opportunity: Despite the challenges and risks associated with the regulatory approval process, CanaQuest's comprehensive strategy, coupled with the expertise of its management and consultants, positions the company well to navigate the regulatory landscape and achieve its objectives, making it a compelling investment opportunity.

Investment Ask: Having discussions.

Please feel free to reach out for more information.

Paul Ramsay
CEO & Co-founder, Dir.: 416-704-3040
paul@canaquest.com www.canaquest.com

Cautionary statement regarding forward-looking information:

This Overview contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on current expectations, estimates, forecasts, and projections about the industry in which CanaQuest Medical Corp operates and the beliefs and assumptions of the management of CanaQuest. Forward-looking statements may be identified by the use of forward-looking terminology such as "plans," "expects," "believes," "estimates," "intends," "may," "will," "should," "could," "anticipates," "predicts," "potential," "continue," or similar terms, variations of those terms or the negative of those terms. The forward-looking statements include but are not limited to, statements regarding:

- The anticipated benefits and effectiveness of Drug Candidate, CQ-001, and its potential to treat rare neurological conditions of epilepsy.
- The expected progress and outcomes of clinical trials for CQ-001 and the nutraceutical formulation, Mentanine™.
- CanaQuest’s ability to navigate the regulatory approval process successfully.
- The potential for commercialization of cannabidiol-based pharmaceuticals and nutraceuticals.
- The impact of the executive team appointments on CanaQuest’s clinical trials and regulatory approval processes.

These forward-looking statements are subject to a number of risks, uncertainties, and assumptions about CanaQuest Medical Corp, and there can be no assurance that the expectations of CanaQuest will be realized. Important factors that could cause actual results to differ materially from those in the forward-looking statements include:

- The possibility that clinical trials of CQ-001 may not be successful or may take longer than anticipated to complete.
- Challenges in securing regulatory approvals or changes in the regulatory environment.
- The potential for unforeseen side effects or other safety issues that could interrupt or halt clinical trials or affect patient enrollment.
- The ability to protect intellectual property and to operate without infringing upon the proprietary rights of others.
- Market acceptance of the Company's products and competition from existing products or new products that may emerge.
- The impact of economic, competitive, governmental, technological, or other factors on the pharmaceutical and nutraceutical markets that could affect the Company's operations or financial results.
- The company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated, and the results, cost, and timing of the company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation, may not be as expected.

Investors are cautioned that any forward-looking statements are not guarantees of future performance and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. CanaQuest Medical Corp undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.